New patent expiration for Wellstat Therap drug VISTOGARD – DrugPatentWatch
Annual Drug Patent Expiration for VISTOGARD
Vistogard is a drug marketed by Wellstat Therap and included in one NDA. It is available from a single supplier. There are two patents protecting this drug.
This drug has one hundred and seventy-two patent family members in twenty one countries.
The generic ingredient in VISTOGARD is uridine triacetate. One registered supplier for this compound. Additional details are available on the uridine triacetate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Make Better Decisions with DrugPatentWatch
» Start Your Free Trial Today «
Copyright © DrugPatentWatch. Originally published on new patent expiry for the drug Wellstat Therap VISTOGARD
